newsCDK4/6 inhibitorsmetastatic breast cancer
Palbociclib Extends Progression-Free Survival in HR+/HER2+ Metastatic Breast Cancer: Insights from the PATINA Trial
By MedXY|Feb 2, 2026
The Phase 3 PATINA trial demonstrates that adding palbociclib to maintenance anti-HER2 and endocrine therapy significantly improves progression-free survival in HR+/HER2+ metastatic breast cancer patients, increasing the median duration fro
